NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in developing treatments to promote nervous system repair in the settings of neurotrauma and neurologic disease. NVG-291 is in a Phase 1b/2a clinical trial in spinal cord injury and has undertaken preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Its NVG-291 is a therapeutic peptide targeting nervous system repair.
äŒæ¥ã³ãŒãNGEN
äŒç€ŸåNervGen Pharma Corp
äžå Žæ¥Mar 13, 2019
æé«çµå¶è²¬ä»»è
ãCEOãRogers (Adam H)
åŸæ¥å¡æ°- -
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«- -
æ¬ç€Ÿæåšå°Suite 1703 - 595 Burrard Street
éœåžVANCOUVER
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœCanada
éµäŸ¿çªå·V7X 1J1
é»è©±çªå·16047225361
ãŠã§ããµã€ãhttps://www.nervgen.com/
äŒæ¥ã³ãŒãNGEN
äžå Žæ¥Mar 13, 2019
æé«çµå¶è²¬ä»»è
ãCEOãRogers (Adam H)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã